Treatment with thyroid hormone
Abstract
Thyroid hormone deficiency can have important repercussions. Treatment with thyroid hormone in replacement doses is essential in patients with hypothyroidism. In this review, we critically discuss the thyroid hormone formulations that are available and approaches to correct replacement therapy with thyroid hormone in primary and central hypothyroidism in different periods of life such as pregnancy, birth, infancy, childhood, and adolescence as well as in adult patients, the elderly, and in patients with comorbidities. Despite the frequent and long term use of l-T4, several studies have documented frequent under- and overtreatment during replacement therapy in hypothyroid patients. We assess the factors determining l-T4 requirements (sex, age, gender, menstrual status, body weight, and lean body mass), the major causes of failure to achieve optimal serum TSH levels in undertreated patients (poor patient compliance, timing of l-T4 administration, interferences with absorption, gastrointestinal diseases, and drugs), and the adverse consequences of unintentional TSH suppression in overtreated patients. Opinions differ regarding the treatment of mild thyroid hormone deficiency, and we examine the recent evidence favoring treatment of this condition. New data suggesting that combined therapy with T3 and T4 could be indicated in some patients with hypothyroidism are assessed, and the indications for TSH suppression with l-T4 in patients with euthyroid multinodular goiter and in those with differentiated thyroid cancer are reviewed. Lastly, we address the potential use of thyroid hormones or their analogs in obese patients and in severe cardiac diseases, dyslipidemia, and nonthyroidal illnesses.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Based on body weight, hypothyroid patients with minimal endogenous thyroid function appeared to require LT4 doses between 1.6 and 1.8 μg/kg/day of actual body weight, although some studies estimate higher doses of 2.0-2.1 μg/kg/day for some patient groups.
“Based on body weight, hypothyroid patients with minimal endogenous thyroid function appeared to require LT4 doses between 1.6 and 1.8 μg/kg/day of actual body weight, although some studies estimate higher doses of 2.0–2.1 μg/kg/day for some patient groups (63).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [63]
A reduced therapeutic dose of LT4 is suggested in elderly patients compared to younger subjects, but no focused RCTs are available.
“A reduced therapeutic dose of LT4 is suggested in these patients compared to younger subjects (63), but no focused RCTs are available.”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [63]
Variable impacts on metabolic parameters and quality of life in prior studies may be attributed to the subjective nature of quality-of-life assessments and differing metrics utilized across studies.
“The variable impacts on metabolic parameters and quality of life, as noted in prior studies on T4 + T3 therapy, may be attributed to the subjective nature of quality-of-life assessments and differing metrics utilized across studies [24].”
The doctor-patient relationship is important for medication adherence.
“The doctor-patient relationship plays a key role in achieving adherence to the medication regimen.88”
From Refractory hypothyroidism: unraveling the complexities of diagnosis and management (2023) · cites this paper as [88]
The citation lists haven’t been fetched yet
References 639 · Cited by 259
- Authors
- Biondi, B., & Wartofsky, L.
- Affiliations
- Federico II University Hospital (IT)
- MedStar Washington Hospital Center (US)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2014-01-16
- Volume
- 35
- Issue
- 3
- Pages
- 433-512
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2074798205
- Cited by
- 259
- References
- 639
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 11 · 2023: 15 · 2022: 31 · 2021: 19 · 2020: 19 · 2019: 31 · 2018: 22 · 2017: 27 · 2016: 18 · 2015: 21 · 2014: 12
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hypothyroidism, thyroid hormone replacement, levothyroxine, primary hypothyroidism, central hypothyroidism, TSH suppression, undertreatment, overtreatment, multinodular goiter, differentiated thyroid cancer, pregnancy, infancy, childhood, older adults, obesity, heart disease, dyslipidemia, low T3 syndrome, thyroid hormone analogs
- MeSH terms
- Humans, Hypothyroidism, Thyroid Hormones, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review